Neurocrine leverages a broad, late-stage, and diversified CNS pipeline including multiple Phase III programs targeting major depressive disorder and schizophrenia, with precision medicine advances increasing visibility for future earnings. The company is expanding its sales force by approximately 30% to bolster INGREZZA adoption and broaden prescriber reach, with expectations for INGREZZA to reach ~$3 billion in sales by 2028 and CRENESSITY targeting peak revenues exceeding $1 billion by 2030.
Cyborg Score Rationale
Neurocrine has a Buy consensus rating from 19 analysts as of February 12, 2026, supported by strong product momentum and late-stage pipeline development. However, momentum has cooled after earlier gains with a 12.10% 7-day share price decline, reflecting market concerns about guidance and competition risks.
Top Insights
INGREZZA reached record high new and total prescriptions with 10% quarter-over-quarter and 12% year-over-year sales growth
CRENESSITY delivered better-than-expected sales with $98 million net product sales in Q3, surpassing consensus
2026 strategy focused on sustainable growth for INGREZZA and CRENESSITY while advancing Phase 3 programs including osavampator in major depressive disorder and direclidine
Market sentiment has turned negative due to "disappointing INGREZZA guidance" with investors expecting stronger 2026 sales outlook